




Revefenacin

Revised: June 3, 2019.

CASRN: 864750-70-9



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of revefenacin during breastfeeding. Because the drug is only 3% absorbed orally, it is unlikely to affect the breastfed infant. Long-term use of revefenacin might reduce milk production or milk letdown. During long-term use, observe for signs of decreased lactation (e.g., insatiety, poor weight gain).

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Acidinium, Tiotropium, Umeclidinium

Substance Identification

Substance Name

Revefenacin

CAS Registry Number

864750-70-9

Drug Class

Breast Feeding

Lactation

Parasympatholytics

Muscarinic Antagonists

Bronchodilator Agents